TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Tolerability of Cannabis in Patients Receiving Concurrent Chemoradiation for Glioblastoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Glioblastoma requiring standard care chemoradiation of concurrent Temozolomide and 60 Gy of radiation given over 30 treatments~* Age 21-70~* Able to give informed consent, and comply with study procedures~Exclusion Criteria:~* Meet DSM-V criteria for current major psychiatric illness, such as bipolar disorder, major depression, active suicidal intent, or psychosis that could be exacerbated by the administration of cannabis~* Meet DSM-V criteria for major neurological disorder, such as mild cognitive impairment or neurodegenerative disorders (such as movement disorders, dementia), that could be exacerbated by the administration of cannabis.~* Women who are not practicing an effective form of birth control (condoms, diaphragm, birth control pill, IUD) or currently pregnant.~* Current (weekly) use of cannabis.~* Patients on supplemental oxygen or history of chronic obstructive pulmonary disease (COPD).~* Cardiovascular Disease~* Compromised Immunity~* Patients with a history of substance use disorder other than nicotine, such an opiate use disorder.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Cannabis + Chemoradiation (Type: EXPERIMENTAL): Patients will receive a cannabis strain with high cannabidiol (4.8%) and low Delta-9-THC (3.23%). Patients will smoke the cannabis over a 2 hour session (from 0.5 - 2.0 cannabis cigarettes) before receiving chemoradiation therapy with radiation and concurrent temozolomide.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Willingness and ability to provide written informed consent.~* Diagnosis of Retinal Vein Occlusion with macular edema and central foveal thickness of greater than or equal to 300 microns confirmed by intravenous fluorescein angiography and Optical Coherence Tomography~* Visual Acuity between 20/25 and 5/200~Exclusion Criteria:~* Bilateral Retinal Vein Occlusion~* Vision worse than 5/200 in study eye~* History of myocardial infarction, ischemia, or cerebrovascular accident within 6 weeks of screening~* Concurrent Proliferative Diabetic Retinopathy and/or Maculopathy~* Concurrent Exudative Age-related Macular Degeneration~* Concurrent optic neuropathy with the presence of an afferent pupillary defect~* Previous vitrectomy in the study eye~* Currently pregnant or planning to become pregnant during the duration of the study. Women currently breastfeeding are also excluded.~* Previous treatment for retinal vein occlusion in the study eye~* Any current medical condition which, in the opinion of the investigator is considered to be uncontrolled~* History of allergy or hypersensitivity to study treatment, fluorescein, or any study procedure and treatment related ingredients (e.g. topical anesthetics, betadine, etc.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aflibercept (Type: OTHER): All subjects will receive aflibercept every 4 weeks. Once vascular endothelial growth factor levels become normal and macular edema improves treatment windows will be extended up to every 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Bispectral Index Monitoring on Recovery From Deep Sedation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 3-12 years old children with spastic cerebral palsy receiving botulinum toxin injection with deep sedation~* American Society of Anesthesiologists Physical Status 1-2~Exclusion Criteria:~* Body mass index \> 30 kg/m2~* unstable heart disease~* Anticipated difficult airway including congenital facial or airway anomaly~* Recent upper respiratory tract infection ( \< 2 weeks)~* Gastroesophageal reflux~* Allergy history to propofol, remifentanil or any drug used during procedure

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Group Control (Type: None): Group who maintains deep sedation using the University of Michigan sedation scale (UMSS) score.
- Group BIS (Type: None): Group who maintain deep sedation using Bispectral Index (BIS) score.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Technegas and Xenon-133 Planar Lung Imaging in Subjects Referred for Ventilation Scintigraphy

Study Design Characteristics:
- Allocation: None
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subject at least 18 years of age.~* Subject is a candidate for ventilation imaging.~* Subject must be willing and able to provide informed consent.~* Subject must be stable and able to undergo Xe-133 planar imaging and Technegas planar imaging.~* Subject must be willing and agree to complete study procedures.~* Subject is using adequate birth control, if female and fertile. Adequate birth control is defined as surgical sterilization, hormone contraceptive use or intrauterine device (IUD).~* Female subject of child-bearing potential has a negative urine or serum pregnancy test.~* Subject has had or is scheduled to have a chest X-ray within 24 hours prior to the investigational imaging study.~Exclusion Criteria:~* Subject has been administered any other radiopharmaceutical within a timeframe that might cause interference with study imaging.~* Subject is a pregnant or lactating female.~* Subject has received Technegas in the past.~* Subject has received an investigational drug within 30 days prior to dosing.~* Subject is hemodynamically unstable.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Xe-133 Followed by Technegas (Type: OTHER): Subjects first inhaled active comparator Xe-133, approximately 10 to 30 millicuries (mCi), and ventilation planar scintigraphy was performed per site standard of care procedures for subject medical need. On the same day, following completion of Xe-133 imaging, subjects inhaled experimental Technegas (Technetium-99m labeled carbon particles), approximately 1.1 mCi, and ventilation planar scintigraphy was performed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of Minirin Melt® in Adult Patients With Nocturia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult aged between 19 and 65 years~* Patients having nocturia~* Decision made to prescribe Minirin Melt according to prescription information~* Willingness and ability to provide written informed consent~Exclusion Criteria:~* When patients have habitual or psychogenic polydipsia (resulting in a urine production exceeding 40ml/kg/24hours)~* When patients have a history of known or suspected cardiac insufficiency and other conditions requiring treatment with diuresis~* When patients have moderate and severe renal insufficiency (creatinine clearance below 50ml/min)~* When patients have known hyponatremia~* When patients have secretion Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)~* When patients have hypersensitivity to the active substances or to any of the excipients

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Transient Thermal Behavior and Diabetic Foot

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diabetic subjects (type 1 and 2)~* age above 18 years old~* able to walk~* affiliate to insurance regimen~Exclusion Criteria:~* unable to stay motionless~* pregnancy~* subjects with feet wound

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Study participants (Type: EXPERIMENTAL): Measurements of the temperature of the plantar arch by thermal imaging. Result analysis regarding podologic grade ( 0-1-2-3)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of scleroderma~* Agrees to use an effective form of contraception for 1 month prior to study entry, throughout the study, and for 60 days after completing the study~* Positive serum anti-nuclear antibody titer~Exclusion Criteria:~* Systemic sclerosis-like illnesses associated with environmental, ingested, or injected agents or with other connective tissue diseases~* Significant existing damage to any of the following internal organs:~  * Kidneys, defined as a serum creatinine level greater than 2 mg/dl or renal crisis~ * Lungs, defined as needing supplemental oxygen~ * Heart, defined as left ventricular ejection fraction less than or equal to 40%~ * Gut, defined as pseudo-obstruction or malabsorption requiring total parental nutrition~* Concurrent interventional therapy that might independently influence the outcome of this trial (e.g., D-penicillamine, cyclosporine, interferon-γ, methotrexate, or photophorosis)~* Clinically significant and inadequately medically treated concurrent endocrine, blood, liver, lung, or kidney diseases~* Pregnant~* Recent drug or alcohol abuse~* Documented noncompliance~* Significant psychiatric history~* Therapy with another investigational drug within 4 weeks prior to study entry~* Screening laboratory results exceeding the following limits: hemoglobin level less than 7 gm/dl; white blood cell level less than 3,000/nl; platelet count less than 50/nl; alanine aminotransferase (ALT) level greater than 65 U/L; creatinine level greater than 2 mg/dl

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Participants will receive thalidomide.
- 2 (Type: PLACEBO_COMPARATOR): Participants will receive placebo thalidomide.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Liver Safety Assessment During Ulipristal Acetate Treatment for Uterine Fibroids (LISA)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 18-55 years~* Symptomatic uterine fibroids~* Being prescribed UPA as a treatment for symptomatic uterine fibroids according to regular practice.~Exclusion Criteria:~* Pregnancy~* Breastfeeding~* Previous or active hepatic disease~* Transaminase (AST,ALT) blood levels higher than 3 times the upper normal limit.~* Bilirubin blood levels higher than 3 times the upper normal limit.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- UPA Treatment (Type: None): Women who had completed a full 12-week treatment course of Ulipristal Acetate for symptomatic uterine fibroids since September 2018

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Adjunctive Nitrous Oxide During ED Incision and Drainage of Abscess

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients 18 years of age or older with cutaneous abscesses located on the trunk or extremities that required I\&D were approached and offered participation in the study. Need for I\&D was left to discretion of treating physician.~Exclusion Criteria:~* Abscesses larger than 5 cm in any dimension~* Abscesses located on the face, neck, scalp, hands, feet, perianal, rectal, or genital areas.~* Subjects with underlying conditions that could affect ventilation, perfusion, or metabolism including intubated subjects, history of COPD, subjects with clinical signs of cardiopulmonary instability, major trauma, shock, sepsis, ASA class 3, 4, and 5.~* Those unable to provide informed consent, nursing home residents, age less than 18 years, non-English speaking, pregnant women, subjects under police custody, or physician discretion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nitrous Oxide (Type: EXPERIMENTAL): Patients undergoing incision and drainage of abscess will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive Nitrous Oxide gas via a gas mixer device while undergoing standard incision and drainage of cutaneous abscess using lidocaine local anesthesia administered subcutaneously. The device will mix and deliver nitrous oxide and oxygen in a 1:1 ratio, at a fixed concentration of 50%/50%. The on demand valve requires patient inspiration to trigger dosing.
- Oxygen (Type: EXPERIMENTAL): Patients undergoing incision and drainage of abscess will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive 100% oxygen gas via the Nitrous Oxide gas mixer device while undergoing standard incision and drainage of cutaneous abscess using lidocaine local anesthesia administered subcutaneously. The device will deliver only oxygen at a fixed concentration of 100%. The on demand valve requires patient inspiration to trigger dosing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Potential Biomarkers of the Severity of Endothelial Damage in End-stage Chronic Kidney Failure

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient who have been informed about the research~* Patients with national health insurance cover~* Patients aged between 18 and 75 years~* Patients with stage 3 kidney failure (30 ml/min \< cl creat \< 59 ml/min) diabetic or not~* Patients with stage 5 kidney failure (cl creat \< 15 ml/mn) diabetic or not and requiring dialysis.~Exclusion Criteria:~* Patients under guardianship~* Pregnant or breast-feeding women~* Infection (including peritonitis in peritoneal dialysis, infection of the catheter insertion site),~* Neoplastic disease,~* Systemic diseases in flare,~* Patients positive for Human Immunodeficience Virus (HIV),~* Patients on immunosuppressants~* Patients taking antioxidants (selenium, vitamin C and/or E)~* Patient on statins

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- group with stage 3 kidney failure (diabetic or not) (Type: OTHER): None
- group with stage 5 kidney failure (diabetic or not) (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Pulmonary Vein Ablation Versus Amiodarone in the Elderly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 65 years at moment of screening, able to sign informed consent.~* Documented paroxysmal AF in association with complaints in the last year, with at least 2 episodes of complaints attributed to AF in the previous 2 months.~* Paroxysmal AF documented with at least one ECG with sinus rhythm not after cardioversion in the last year.~* No prior use of amiodarone in the last 6 months and no usage longer than 4 weeks in total.~Exclusion Criteria:~* EF \< 35 % or description of poor left ventricular function on echocardiogram. Measurement should not be older than 6 months at moment of screening.~* Aortic, mitral, pulmonary or tricuspid valve regurgitation or stenosis, if graded severe (grade \>3)~* Acute illness: unstable angina, infectious disease.~* Primary structural or electrical heart disease: dilated cardiomyopathy, hypertrophic cardiomyopathy, Brugada syndrome, long QT syndrome.~* Reversible causes (thyroid dysfunction, uncontrolled hypertension, ischemia).~* Previous ablation.~* Contraindications for amiodarone; liver dysfunction (serum alanine aminotransferase \>2.5 times upper limit); thyroid dysfunction; chronic lung disease; baseline QTc \>460 ms. sinus node dysfunction (pause more than 3 seconds in sinus rhythm); second or third degree AV-block.~* Contraindications for anti-coagulation: prior life threatening hemorrhage under use of Vitamin K antagonists.~* Any myocardial infarction or PCI in previous 6 months.~* CABG in previous 6 months.~* Renal dysfunction: creatinine clearance \<45 ml/min~* Severe co-morbidity. Life expectancy less than 1 year.~* Thrombus in left atrium~* Untreatable allergy to contrast media

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PVI ablation (Type: EXPERIMENTAL): Pulmonary Vein Ablation
- Amiodarone medical treatment (Type: ACTIVE_COMPARATOR): Amiodarone medical treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Antidepressive Effect of rTMS as add-on to ECT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients admitted to the Psychiatric Hospital of Aarhus~* Patients referred for ECT~* Age 18-80 years~* Moderate or severely depressed patients (ICD-10(DSM-IV)~* HAM-D score (17-item) ≥20 and/or Ham-D subscale ≥10.~Exclusion Criteria:~* Organic brain disease~* Epilepsy or disposition to epilepsy~* Metallic objects in chest or brain~* Cardiac pacemaker~* Somatic diseases associated with brain dysfunction~* Pregnancy~* Severe agitation or delirium~* Alcohol or drug dependence (ICD-10)~* Use of coercive measures~* The patient does not wish to participate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- low frequency rTMS (Type: EXPERIMENTAL): Right prefrontal Low frequency (1 hz) repetitive transcranial magnetic stimulation, administered with 2 sessions each week
- Sham-rTMS (Type: SHAM_COMPARATOR): Sham right prefrontal rTMS 2 times a week

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Irinotecan Discontinuation and Reintroduction for Advanced Colorectal Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven adenocarcinoma of colon and rectum~* No prior chemotherapy or only adjuvant chemotherapy and/or radiotherapy~* Advanced, metastatic or recurrent not amenable to curative local therapy~* Measurable lesion(s)~* ECOG performance status 0 to 2~* Normal marrow, hepatic and renal function~* Provision of written informed consent~Exclusion Criteria:~* Active infection and/or severe comorbidity~* Known history of anaphylaxis of any origin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues